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Abstract: Neuroleptic malignant syndrome is an unpredictable iatrogenic neurologic 
emergency condition, mainly arising as an idiosyncratic reaction to antipsychotic agent use. 
It is characterized by distinctive clinical features including a change in mental status, general-
ized rigidity, hyperpyrexia, and dysautonomia. It can be lethal if not diagnosed and treated 
properly. Mortality and morbidity attributed to this syndrome have recently declined markedly 
due to greater awareness, earlier diagnosis, and intensive care intervention. In most cases, the 
syndrome occurs as a result of a rapid increase in a dose of neuroleptic, especially one of the 
long-acting ones. Pathophysiology behind this syndrome is attributed to a dopamine receptor 
blockade inside the neurons rendered by the offending drug and excessive calcium release from 
the sarcoplasmic reticulum of skeletal myocytes. Laboratory tests, although not diagnostic, 
may assist in assessing the severity of the syndrome and also the consequent complications. 
The syndrome has been described in all age groups and occurs more in males than in females. 
Genetics appears to be central regarding the etiology of the syndrome. Stopping the use of the 
offending agent, cold intravenous fluids, and removal of the causative agent and its possible 
active metabolites is the cornerstone of treatment. Periodic observation of psychotic patients 
recently started on antipsychotic medications, especially those being treated with depot prepara-
tions, may aid to an early diagnosis of the syndrome and lead to early treatment.
Keywords: neuroleptic malignant syndrome, dopamine receptors, rhabdomyolysis, renal 
shutdown, hyperpyrexia, sarcoplasmic reticulum
Introduction
Prelude and history
Neuroleptic malignant syndrome (NMS) is a neurologic emergency condition that may 
arise as a result of administration of potent psychotropic agents. Its pathophysiology 
is still unclear. It includes the following symptoms: muscle rigidity, hyperpyrexia, 
autonomic nervous system imbalance, mental disturbances (manifested mostly as 
delirium), and abnormal metabolic changes. In atypical cases, which are considered 
to be associated with the use of lower potency agents, rigidity may be milder or even 
absent.1 Importantly, hyperpyrexia, an essential diagnostic criterion for NMS, can 
be absent in such cases.2,3 The complexity of making diagnosis is due to the isolated 
occurrence of autonomic malfunction, hyperpyrexia, Parkinsonian-like muscle rigidity, 
and creatine kinase (CK) elevation. Individually, these symptoms are not necessarily 
considered as a precursor of NMS.4,5 It appears that the incidence of this iatrogenic 
ailment has decreased partly due to the discovery of the so-called second-generation 
(nonconventional or atypical) antipsychotics and partly due to the changes in prescrip-
tion guidelines that the psychiatrist follows when treating psychoses and other neuro-
logic conditions that might necessitate the use of these major tranquilizers. If NMS is 
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not diagnosed early and vigorously treated in a fully equipped 
intensive care unit,6,7 then the condition can be fatal or give 
rise to permanent morbid sequelae.8,9 A danger is that NMS 
can be easily overlooked, especially after the prescription of 
nonconventional antipsychotic agents as first-line treatment 
to combat psychoses, especially schizophrenia. The major 
tranquilizers were discovered in 1956 and clinically used in 
1960 by a French group, who studied the effects of the potent 
conventional antipsychotic, haloperidol. They described 
the syndrome that was given the French name “syndrome 
malin des neuroleptiques”, later translated into English and 
termed NMS.10,11
Contributing risk factors
Strong evidence shows that a genetic defect is a major risk 
factor. Identical twins and a mother with her two daughters 
were presented with NMS.12 Senile dementia of Lewy-type 
(another potential contributing factor) is characterized by the 
presence of protein aggregates (α-synuclein and ubiquitin) in 
neurons of these individuals, usually detected as a postmortem 
finding in the brain. In the USA alone, 1.3 million individu-
als are affected by this type of dementia.13 It is unclear why 
males 40 years of age are at a greater risk of developing 
NMS (male:female ratio is 2:1).14,15 This could be attributed to 
1) the higher use of antipsychotics in men of this age group, 
2) the adherence to medication, 3) differences in pharma-
cokinetics toward the drug and the pharmacodynamics of the 
drugs in the patients of different sexes, and 4) other factors 
not yet fully elucidated.16–19 Point 3 is not totally accepted, 
and this is indeed of controversial nature.20 Postpartum 
women are liable to develop psychiatric diseases, such as 
psychosis and depression, and thus they are likely to use 
psychotropics, therefore are at risk of suffering from NMS.21 
The most obvious risk factor related to the development of 
NMS is neuroleptic therapy itself. Thus, the time-course of 
administering the drug, the type of neuroleptic used (high-
potency drugs endanger most), rapid titration of the desired 
therapeutic serum levels, and the oily long-acting depot forms 
of neuroleptics (such as haloperidol decanoate, risperdal 
consta, fluphenazine decanoate, and fluphenazine enanthate) 
are well-established risk factors regarding the development 
of NMS.22–24 Previous episodes of NMS, a recent episode of 
catatonia, and extreme agitation are documented risk factors. 
This is because these conditions are over represented in this 
patient group, and thus NMS might be overlooked,25–28 or 
at least not diagnosed early enough. The incidence of NMS 
is ~0.2%–3.23%.14 The reported numbers are probably low 
because physicians and psychiatrists have become aware of 
the serious side effects that neuroleptics can cause, even the 
most recently designed ones.23,29
Origin and proposed theories
The molecular basis of NMS is attributed to a sudden 
pronounced reduction of dopamine activity. This might 
be due to the withdrawal of dopaminergic agents or to the 
reduction in dose, or from the antagonism of dopamine recep-
tors with antipsychotics or other dopamine-antagonizing 
preparations. In schizophrenic patients, it has been pro-
posed that proinflammatory cytokines such as interleukin 1 
(IL-1)-α, IL-6, and tumor necrosis factor, are involved in 
mechanisms that lead to development of neuroleptic intol-
erance. These proinflammatory cytokines activate the key 
kynurenine enzymes: indoleamine 2,3-dioxygenase and 
kynurenine-3-monooxygenase that catalyzes the production 
of 3-hydroxykynurenine (3-HK). In NMS, the existence of 
this harmful biomaterial (3-HK) initiates the activation of the 
scavenging process carried out by the microglia (macrophages 
of central nervous system [CNS]) to produce the neurotoxin 
quinolinic acid instead of neuroprotective kynurenic acid 
(KYNA).30,31 A potential decrease in the KYNA pool will 
diminish firing rates and burst firing activities of dopamine 
neurons of the midbrain with decreased intake and uptake of 
the amino acid tyrosine, which is attributed to dysphagia and 
physical hypoactivity because of muscle rigidity and altered 





 is an essential cofactor of the aromatic amino 
acid hydroxylase enzymes used in degradation of phenylala-
nine and the biosynthesis of certain neurotransmitters includ-
ing dopamine, and it is a cofactor in production of NO. This 
decrease in the BH
4
 pool will affect nigrostriatal dopamine 
neurons, causing a deficiency in dopamine biosynthesis.33
BH
4
 is related to the free radical NO. NO dilates blood 
vessels, inhibits thrombocyte activity,34 and reduces the 
sympathetic vasoconstriction responsiveness, both in resting 
and contracting skeletal myocytes.35,36
Failure in the NO system results in the accumulation of a 
large amount of free radicals that impairs the mitochondrial 
electron transport chain, thus decreasing the cellular produc-
tion of adenosine triphosphate (ATP).37 As a result, muscle 
cells are damaged, causing hyperpyrexia, and cellular con-
stituents, for example, electrolytes (potassium, phosphate) 
and proteins (myoglobin, creatine, and CK) leak into the 
blood stream. 
One of the motives behind design of second-generation 
antipsychotics was for treatment of NMS. Unfortunately, 
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causing this syndrome. For example, clozapine, olanzapine, 
risperidone, quetiapine, and ziprasidone have been criticized 
for being causative agents.23 Actually, the potent nonselective 
dopamine receptor (D) antagonist neuroleptics, such as halo-
peridol (a butyrophenone), promethazine, and chlorpromazine 
(phenothiazines) are well-known causative factors behind this 
secondary drug effect.38 Dopaminergic drugs, for example, 
levodopa, used in Parkinson’s disease, especially when 
abruptly discontinued25 may induce NMS as a side effect. 
It is known that the antiemetic metoclopramide (a chlorben-
zamide derivative), expressing antidopaminergic action, can 
cause NMS.39 Importantly, the hematologic and biochemical 
changes seen in NMS, such as leukocyosis and elevated serum 
CK levels, are a result of the use of an antipsychotic. These 
agents enhance calcium release from the sarcoplasmic reticu-
lum of skeletal myocytes, ultimately causing muscle rigidity 
and eventually rhabdomyolysis.40 NMS as a side effect has 
also been reported following the use of other drugs that are 
not known to have antidopaminergic potential. It is evident 
that many drugs used in treatment of psychiatric diseases are 
not antipsychotic agents (Table 1).11,41–43
Landmarks of recent directions 
in research
The most important of these are the 
following
First, regarding dopamine receptor blockade and the conse-
quence of reduced dopamine activity, it was in the past belief 
that psychosis was a result of high neurotransmitter levels in 
dopaminergic neurons and its action on dopamine receptors, 
especially those of dopamine subtype 2 receptors (D
2
). One 
reason for designing atypical antipsychotics was to have at 
hand agents with lower D
2
 receptor affinity (the proposed 
target receptors of the vast majority of conventional psycho-
tropics). Unfortunately, these new agents were also capable 
of causing NMS.
Second, recent studies indicate a genetic defect as a 
component in NMS,44 and this actually supports sympathoa-
drenal hyperactivity as another etiologic model in NMS. This 
would imply that a defect in calcium regulatory enzymes 
within the autonomic sympathetic neurons probably has an 
initiating role in the pathophysiology of this syndrome.45 
This would in fact link the syndrome to what is known as 
malignant hyperthermia, where NMS is considered as the 
neurogenic variant of this condition. Furthermore, both 
conditions are closely linked to a defect in synthesis of 
calcium-related proteins.
Clinical features of the neuroleptic 
syndrome
It is evident that the clinical presentation of NMS is not 
homogeneous. Indeed, the clinical signs/symptoms are 
rather heterogeneous, making diagnosis difficult, especially 
in the early phase.46 NMS usually starts as an unexplainable 
collection of several symptoms: tremor and muscle cramps, 
unstable blood pressure, and disturbance of mental status, for 
example, anxiety, agitation, delirium, and fulminant coma 
(terminal stage).
Muscle rigidity in NMS is most likely caused by blockade 
of dopamine D
2
 receptors and can occur in many forms. 
Choreiform movements can also be seen in some cases of 
NMS. Caution should be taken here, because drugs other 
than antipsychotics can cause this unwanted effect such as 
anticonvulsants and levodopa.47,48 Oculogyric crisis, can 
be manifested in NMS especially when the intoxication 
is induced by haloperidol, chlorpromazine, fluphenazine, 
Table 1 A list of some known drugs (of different categories) that 





Chlorpromazine Conventional antipsychotic, anticholinergic, 
and antihistaminic
Citalopram SSRi antidepressant
Clozapine Potent nonconventional antipsychotic
Desipramine Antidepressant, tricyclic
Domperidone Dopamine antagonist, antiemetic
Dosulepine Antidepressant, tricyclic
Droperidol Antipsychotic, antiemetic, and neuroleptanalgesic
Fluphenazine Conventional antipsychotic
Haloperidol Potent conventional antipsychotic




Perphenazine Potent conventional antipsychotic
Phenelzine Antidepressant, anxiolytic, and irreversible 
nonselective MAOi
Prochlorperazine Antiemetic, conventional antipsychotic









Abbreviations: MAOi, mono amine oxidase inhibitor; SSRi, selective serotonin 
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or olanzapine.49 Clinicians have to take into consideration 
that oculogyric crisis can also be seen in certain forms of 
epileptic fits (versive seizures).
According to an analytic study of a population of NMS 
cases, 70% demonstrated the following sequence of events 
ending in coma at the terminal phase: mental status changes 
appear first, followed by rigidity, then hyperpyrexia, and 
finally autonomic dysfunction (dysautonomia).50 Dysauto-
nomia may include diaphoresis, nausea, vomiting, unstable 
blood pressure, and cardiac arrhythmias.
Importantly, hyperpyrexia can be delayed for .24 hours 
(after the appearance of the first symptoms). This might lead 
to diagnostic confusion even among expert clinicians.51 The 
substantial variations that occur in clinical presentation have 
to be taken into consideration, and the signs and symptoms 
need to be evaluated twice before a final diagnosis of NMS 
can be made. Clinicians have to be aware that signs and 
symptoms presented in NMS, related to atypical antipsy-
chotic agents, differ from those seen with older (typical) 
remedies.52 Once the above-mentioned symptoms have 
appeared, then progress occurs very rapidly and the classical 
clinical picture appears within 2–3 days. In certain cases of 
NMS, one can observe sialorrhea (ptyalism). This is hyper-
salivation, which can cause drooling if dysphagia coexists. 
Sialorrhea in NMS can also cause aspiration pneumonia, 
as stated elsewhere. This reflects the significance that NMS 
patients are best admitted to intensive care unit (ICU), where 
nasogastric and endotracheal tubes can be instituted easily by 
expert personnel, when necessary. Hypersalivation probably 
will be more prominent when NMS is caused by clozapine 
and/or amisulpride, as these two agents can manifest this 
unwanted effect. Hematologic and biochemical changes 
are then inevitable: leukocytosis and elevated serum CK 
levels, which are attributed to hyperkinesia and subsequent 
rhabdomyolysis.53 The patient may suffer hypertensive 
crisis (resultant of dysautonomia), hyperpyrexia, and finally 
metabolic acidosis (coma). Almost 50% of patients show an 
unexplained slow pattern of electroencephalographic (EEG) 
changes.54 It has been hypothesized that these EEG findings 
can be attributed to changes in neuronal pathways result-
ing from the blockade of dopamine receptors.55 The exact 
pathophysiology behind hyperpyrexia is also unclear but is 
believed to be associated with the blockade of the hypotha-
lamic dopamine receptor.56
Differential diagnosis
The dilemma of differential diagnosis in NMS is sometimes 
further complicated by the paradox of coexisting pathologies 
giving a similar clinical picture, such as myxedema crisis 
resultant of hypothyroidism and other pathologies, for 
example, catatonia of different underlying reasons.57
Another situation is where skin burns coexist with NMS 
(although a rare coincidence),58–60 giving rise to diagnostic 
difficulties, because these two situations have many similar 
symptoms in common, although differing in etiology. The 
problem with the above-mentioned disorder (NMS concomi-
tant with hypothyroid crisis) is that both conditions can be 
precipitated by antipsychotic use (ie, occur as side effects). 
In fact, these two pathologies are the opposite of one another, 
NMS being a hypermetabolic state whereas hypothyroid 
crisis is a hypometabolic one. This is the reason why the 
latter (hypothyroid crisis) can curtail the classic clinical 
manifestations of NMS.61
In all suspected NMS cases, a careful review of drug 
intake by the patient is mandatory, moreover, a broad list 
of differential diagnoses in all cases of hyperpyrexia and 
rigidity, should be drawn-up and evaluated.62
Clinical findings in NMS can sometimes be easily 
misinterpreted by a nonexpert as being symptoms of a 
nontreated mental illness.63 The likelihood of developing 
NMS is very small in the following patient groups: 1) those 
already admitted to a psychiatric institution, being stabilized 
during a therapeutic period with constant maintenance doses 
of psychotropics and 2) those who neither have a history 
of medicament incompliance nor the intake of psychedelic 
substances that could worsen their psychosis, and were thus 
subjected to an increase in their doses of antipsychotics.
On a clinical basis NMS should be carefully distin-
guished from the following clinical categories: encephalitis, 
toxic encephalopathy, malignant hyperthermia, heat stroke, 
serotonin syndrome (selective serotonin reuptake inhibitors 
[SSRIs] toxicity), malignant catatonia (neurogenic motor 
immobility),64 and status epilepticus.42,65
As one can see, some of these above-mentioned cat-
egories are related to NMS, such as 1) serotonin syndrome, 
2) malignant hyperpyrexia, 3) malignant catatonia, and 
4) clozapine-induced hyperpyrexia. Here, clinical expertise 
is the most important tool used to distinguish these from 
true cases of NMS.
Serotonin syndrome
This is the most common diagnosis related to NMS. It is one 
of the serious side effects of SSRI. Patients who have a simi-
lar presentation makes it difficult to be distinguished from 
NMS.66 Milestones that characterize serotonin syndrome 
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Other minor features include gastrointestinal symptoms such 
as diarrhea, nausea, and vomiting, which are rarely seen in 
NMS. If present, rigidity and hyperpyrexia are milder here 
than anticipated in NMS.
Malignant hyperpyrexia
This is a genetic disorder, usually triggered by the inhalation 
of potent halogenated anesthetics (eg, halothane) or depolar-
izing neuromuscular junction blockers such as succinylcho-
line and during induction of general anesthesia. Symptoms 
are hyperthermia, muscle rigidity, and dysautonomia, identi-
cal to that in NMS, though in a more abrupt manner.
Malignant catatonia
Poses a dilemma when to be differentiated from NMS. It 
shares hyperpyrexia and rigidity with NMS, but it differs in 
the existence of prodromal behavioral symptoms (of some 
weeks), such as psychosis, agitation, and catatonic excite-
ment. The motor symptoms of malignant catatonia are dys-
tonia, waxy flexibility, and repetitive stereotypic movements. 
These form a category distinct from that usually seen in 
NMS.69,70 These two below-mentioned disorders can thus give 
rise to diagnostic challenges and thereby produce controversy 
among clinicians because they are very difficult to distinguish 
from one another on a clinical basis alone.28,44,71
Clozapine-induced hyperpyrexia
Clozapine is a major atypical neuroleptic agent recommended 
in the treatment of resistant schizophrenia.72 It has proved its 
effectiveness in treating both negative and positive symp-
toms in patients with refractory (resistant) schizophrenia, 
a reason that accounts for its frequent use. The drug has 
a spectrum of side effects (not discussed in this review), 
importantly including fever which is mentioned here.73 
Clozapine-induced hyperpyrexia is a known common side 
effect following the use of this antipsychotic,74 usually being 
encountered within the first 4 weeks of treatment and has 
a prevalence that varies from 0.5% to 55%.75,76 It lasts for 
2.5 days on average and if treatment is not discontinued then 
fever abates between 8 and 16 days.77 This condition can be 
considered as a variant of NMS.78 There is also a miscella-
neous group of unrelated neurologic and medical disorders 
that should be taken into consideration with regard to dif-
ferential diagnosis in NMS patients. The clinical symptoms 
of these disorders can overlap and mimic those of NMS. This 
is especially true for patients with extrapyramidal side effects 
(EPS) resulting from concomitant antipsychotic use. These 
disorders are listed in Table 2 and should not be overlooked 
because they have serious implications for both prognosis 
and treatment.1,42
Is NMS avoidable or inevitable?
This is a perplexing question to answer. In recent years, 
there has been an increase in the use of antipsychotics in 
cases other than psychoses such as in treatment of trauma 
patients, for example, burns58 and other situations where 
pain is the chief complaint (eg, neuritis and migraine).79 It is 
true that nowadays one is more aware of NMS, and there 
are clear general rules concerning the therapeutic doses of 
many neuroleptics. New remedies are constantly coming 
into the drug market for therapeutic use. It can be difficult 
to predict what side effects a new drug are likely to initiate, 
even if this drug has passed phase 2 or even phase 3 stages. 
These new agents could be neuroleptics or agents belonging 
to other drug groups. On an accumulative basis many drugs 
can produce side effects, that is, after prolonged use with 
successive doses (not as an idiosyncratic side effect of a 
single dose). As mentioned elsewhere in this review, drugs 
Table 2 Unrelated disorders as elements necessary to be differentially diagnosed from neuroleptic malignant syndrome
Category Description Detail
CNS infections Meningitis, encephalitis, tetanus
Diseases Autoimmune encephalitis, seizures, CNS vasculitis
Trauma Acute hydrocephalus 
Acute spinal cord injuries
Systemic infections Pneumonia, sepsis
endocrine diseases Thyrotoxicosis
Pheochromocytoma
Drugs intoxication Phencyclidine, ecstasy, cocaine, amphetamine, lithium salts
impaired thermoregulation Neuroleptics can predispose heat stroke
withdrawal intrathecal baclofen
Neuromuscular Acute dystonia Muscle rigidity
Porphyria CNS and dermatologic types Accumulation of porphyrin in the body
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of very different categories can precipitate NMS, thus it is 
not exclusively induced by neuroleptics.
How to approach a suspected case 
of NMS
A history of rapid dose escalation of the psychotropic agent 
being used, or a switch from one agent to a more potent one, 
especially a depot parenteral preparation, or even sometimes 
a switch from one agent to another of the same potency, 
should raise an alarm suggesting NMS, especially whenever 
hyperpyrexia and rigidity are prodromal features.22,26,27,80 As 
mentioned, there is no diagnostic laboratory test for NMS. 
Laboratory data only strengthen diagnosis or at least reduce 
the number of other possibilities. The parameters shown in 
Table 3, as suggested by intensive care units, are usually 
requested. Importantly, the results of blood tests in cases of 
NMS are usually the following: leukocytosis, thrombocytosis 
(very rarely thrombocytopenia81), thick serum (because of 
rhabdomyolysis), and dehydration (because of hyperpyrexia). 
The rigidity and hyperpyrexia in NMS contribute to muscle 
damage (necrosis of skeletal myocytes) that explains the 
elevated levels of the following biochemical parameters: CK, 
liver function tests (aspartate aminotransferase and alanine 
aminotransferase), and lactate dehydrogenase. A CK level 
that exceeds 1,000 IU/L is a useful indicator for NMS,82–85 
moreover, the degree of elevation reflects the severity of 
the condition, giving a clue regarding prognosis.51 The 
increase can be as high as 10,000 IU/L.4,44,86–88 Basically, 
the increase is not pathognomonic in diagnosis89 nor is any 
other positive laboratory parameter alone. This is because CK 
levels can be within the normal physiologic values especially 
when the muscle rigidity is not clearly developed, particularly 
in the early onset phase of NMS. Some clinicians attribute 
mild increases in CK levels to be a result of intramuscular 
injections and physical restraints (especially in catatonic 
psychotic patients) and sometimes idiopathic, without having 
any logical specific explanation.45,86
Necrosis of skeletal myocytes progresses quickly to rhab-
domyolysis, in turn leading to myoglobinemia, hyperkalemia, 
hyperphosphatemia, hypercalcemia, and hyperuricemia. In a 
study on 1,346 NMS patients, rhabdomyolysis was reported 
as the most prevalent complication (30.1%) compared to 
other associated complications.90 Electrolyte imbalances can 
cause serious cardiac arrhythmias that may end up in cardiac 
arrest if not treated promptly. Both classes of antipsychot-
ics, which are the main causal actors of NMS, can cause 
serious cardiac side effects regardless of electrolyte imbal-
ance; orthostatic hypotension is one of these. This undesired 
autonomic side effect can also be encountered with atypical 
antipsychotics, for example, clozapine. Among the typical 
antipsychotics, the low potency agents (phenothiazines) 
are most commonly known to cause this undesired effect.91 
The other serious side effect psychotropic agents can cause is 
the prolongation of the QT interval. This electrocardiographic 
finding has a pivotal clinical relevance, as this can cause 
life-threatening cardiac arrhythmias, the worst of which is 
torsades de pontes and sudden death.92 This serious cardiac 
side effect has been seen in patients who have been treated 
with amisulpride, pimozide, sertindole, thioridazine, and 
ziprasidone.93 Clinicians should be aware of these side effects 
when regarding a case of NMS. Another problem is myo-
globinemia that leads to myoglobinuria which can ultimately 
promote renal failure.51,94 A low serum iron concentration of 
5.71 μmol/L (normal value: 11–32 μmol/L) is frequent in 
NMS. Although sensitive in 92%–100% of cases it is not a 
pathognomonic biochemical marker for NMS.88,95 Clinicians 
need to investigate other possibilities behind hyperpyrexia, 
depending on the dimensions of the manifested clinical 
picture. Other reasons causing fever have to be ruled out, for 
example, infections of the urinary tract, respiratory system, 
and CNS (encephalitis and meningitis). Blood, urine, and 
cerebrospinal fluid (CSF) culture and sensitivity tests should 
be requested. Examination of CSF can exclude meningitis 
Table 3 Suggested workup blood tests required when neuroleptic 
malignant syndrome is suspected
Requested test Why requested
Complete blood picture To exclude leukocytosis and 
all kinds of hemolysis and its 
consequences
Blood cultures To exclude possibilities of septic 
shock (coma)
LFTs To exclude hepatic failure for one 
reason or another
BUN and creatinine levels To exclude renal failure
Calcium, phosphate, potassium,  
and sodium levels
To exclude electrolyte imbalances 
and hemolysis
CK level To exclude or prove rhabdomy-
olysis or other myocytes type 
necrosis
Serum iron level Because of rhabdomyolysis and 
other hemolytic pathologies
Urine myoglobin level To exclude myoglobinuria
Arterial blood gas analysis To exclude respiratory failure and 
metabolic acidosis
Coagulation studies To exclude hepatic failure and DiC
Serum and urine toxicologic 
screening
To exclude ASA, cocaine and 
amphetamines poisoning
Abbreviations: ASA, acetyl salicylic acid; BUN, blood urea nitrogen; CK, creatine 
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as being causative of fever (pyrexia of an unknown origin) 
and disturbed mental status.
Concerning imaging (computerized axial tomography 
[CAT] or magnetic resonance imaging [MRI]), this investi-
gation is not strongly recommended since it does not yield 
urgent diagnostic aid for NMS. Imaging will only rule out 
structural lesions in the CNS, such as tumors, intracranial 
hemorrhage, or head injuries that can possibly lead to coma. 
Certain cerebral hemorrhages such as pontine hemorrhage 
can initiate the onset of pyrexia.96,97 Thus, cerebral imaging 
techniques might afford a useful tool to rule this out or other 
above-mentioned possible diagnostic categories. Some 
neurologists believe that MRI should be performed very 
urgently whenever NMS is suspected in order to rule out 
autoimmune encephalitis.98,99 If this is diagnosed then one 
can start treatment with immunosuppressive agents. In 
this sense, MRI is preferred over CAT scanning because 
it will be more informative.100,101 To exclude aspiration 
pneumonia (Mendelson’s syndrome) and consequent respi-
ratory failure, chest X-ray is usually requested. The values 
of laboratory parameters found in a typical case of NMS are 
shown in Table 4.
Management and lines of treatment
Management should be started actively once the syndrome 
is suspected, that is, when the individual has the criteria 
mentioned above. He/she should be admitted to a well-
equipped ICU with circulatory and ventilator support. 
Active treatment should commence immediately, generally 
including, first, the removal of the offending agent and effects 
of its active metabolites (whenever possible) and second, 
cooling down the patient using cooling blankets and applying 
ice-packs to the groin and axillae.
The optimal pharmacologic treatment is still to be elu-
cidated, and there is no general agreement among clinicians 
(especially between internalists and doctors in an ICU) 
concerning the therapeutic significance of currently used 
drugs to treat NMS. In fact all these drugs are administered 
for symptomatic treatment of the complications, not the 
syndrome itself.
Being a rare condition, most of the published work 
regarding the lines of treatment of NMS are based on case 
reports, meta-analysis, or opinions of experts in the field.46 
In general, one can say that there are two basic lines of treat-
ment, one being a biological approach and the other parallel 
supportive therapy.62
Biological treatment
Dantrolene has been recommended as a muscle relaxant for 
treating muscular rigidity, and dopamine-agonist drugs such 
as bromocriptine have proved to be beneficial.102 Due to its 
dopaminergic and anticholinergic pharmacologic effects, 
amantadine is another alternative. Apomorphine may be 
used, but still it is not an optimal choice because it is not 
supported by major evidence.103 Minor tranquilizers such 
as benzodiazepines are a good choice for treating agitation 
and catatonia. The benefits achieved by the above-mentioned 
drugs are claimed to be uncertain, at least by some research 
groups.104 The evidence that supports the use of the above-
mentioned agents actually is limited because 1) these agents 
are frequently used anecdotally, since they lack scientific 
evidence regarding efficiency, 2) absence of evidence-based 
optimal pharmacologic treatment, and 3) high morbidity and 
mortality rates in this syndrome. Electroconvulsive therapy 
(ECT), which has been suggested by certain groups, has no 
proven empirical benefits. The reason for its use in NMS 
though is attributed to its efficacy in treating malignant 
catatonia and Parkinsonism.105,106 One further issue can 
be mentioned in this context: the drive for the use of ECT 
comes from the frequent need for psychotropic agents in a 
setting where these cannot be used.107 The mainstay of the 
Table 4 Laboratory data expected to be seen in a typical case of 
neuroleptic malignant syndrome
Parameters Changes
Enzymes and abnormal protein in plasma
LDH increased
CK increased in (50%–100% of cases)
ALP increased
ASAT and ALAT increased
Myoglobin Myoglobinemia





Sodium Hypo or hypernatremia
Uric acid Hyperuricemia
Urea Uremia (increased BUN)
Serum iron Decreased
Elements of blood
Leukocytes Leukocytosis (70%–80% of cases)
Blood platelets (thrombocytes) Thrombocytosis 
(thrombocytopenia*)
Urine
Protein Proteinuria (increased protein)
Myoglobin Myoglobinuria (increased 
myoglobin)
pH (blood gas analysis) Decreased (metabolic acidosis)
Note: *very rarely, for more information see the study by Ghani et al.81
Abbreviations: ALP, alkaline phosphatase; ALAT, alanine aminotransferase; ASAT, 
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treatment is, thus, supportive once having ceased the use of 
the offending drug(s).
Complementary supportive treatment
Comatose NMS patients should have an open intravenous 
(IV) channel for administration of fluid and, if necessary, 
drugs. The purpose of IV fluids is to avoid dehydration 
resulting from hyperpyrexia and to avoid acute renal 
failure because of highly elevated blood myoglobin that 
may induce renal damage. This can be avoided by aggres-
sive (contentious) intravenous hydration with cooled IV 
fluids to induce alkalization of urine and diuresis. These 
measures can prevent renal failure and enhance excretion 
of the by-products of muscle breakdown. One should also 
consider prophylactic endotracheal intubation in patients 
with excessive salivation (sialorrhea) to avoid aspiration 
pneumonia, dysphagia, hypoxemia (in case use of a venti-
lator is evaluated), metabolic acidosis (successive perfor-
mance of blood gas analysis, with a display of blood pH), 
severe rigidity with hyperthermia and coma. A nasogastric 
tube might be necessary to feed comatosed patients, par-
ticularly if the coma situation prevails longer than expected, 
or when necessary according to a clinical evaluation. With 
these supportive techniques, symptoms will resolve within a 
couple of weeks or so, or longer (~4 weeks) if the syndrome 
was initially brought about by long-acting antipsychotics 
(ie, depot injections).
Prognosis
Concerning the prognosis of this syndrome, this is mainly 
dependent on early diagnosis and active intervention with-
out delay in a well-equipped ICU. Although the majority of 
cases can be successfully managed, we still have to be aware 
that ~10% of cases can be fatal, regardless of early diagnosis 
and treatment. Hyperpyrexia, rhabdomyolysis, and neuronal 
damage can lead to amnesia (memory impairment), which 
could be temporary or persistent in certain cases.108 Among 
the elderly, acute respiratory failure, acute renal shutdown, 
infections (septic shock), and coexisting congestive heart 
failure are significant predictors of mortality in this rare 
syndrome. The acute respiratory insufficiency is the strongest 
independent mortality prognosticator.90
What if the patient needs an antipsychotic after recovery 
from this syndrome: should an antipsychotic be prescribed 
or not? A question difficult to answer. The majority of 
psychiatric centers recommend a drug from the atypical 
group (second-generation or nonconventional) of a low-
potency type.42
Discussion and future perspectives
NMS is a life-threatening iatrogenic neurologic emergency, 
usually but not always associated with the administration of 
psychotropic drugs and manifested as a characteristic clini-
cal syndrome. One should expect the occurrence of NMS in 
Parkinson’s patients, especially those treated with levodopa 
preparations, where these suddenly have been reduced or 
withdrawn as an iatrogenic mishap, or because of the com-
plications initiated by the drug.44,80,86,109 Regardless of clinical 
alertness, it might not be easy to differentiate NMS from a 
case of, for example, adrenocorticotropic hormone (ACTH) 
deficiency. Patients with ACTH deficiency can manifest a 
clinical picture very similar to that of NMS.110,111
In such cases hydrocortisone therapy should be evaluated. 
The incidence of NMS varies widely, ranging from 0.02% 
to 3% among patients on psychotropic drug therapy.44,51 
A wide range variation of this type may reflect the follow-
ing: 1) differences among sampled populations, for example, 
an inpatient versus outpatient, 2) differences in methods of 
surveillance, and 3) definition of the disease itself. All of 
these criteria have a lot to say regarding the wide spectrum 
of statistical values.
The dilemma of how to diagnose this syndrome actually 
originates from the fact that one cannot predict its occur-
rence, in other words, it can occur after an orphan dose of 
a drug (usually antipsychotic) or after continuing therapy 
with the same remedy at the same dose for many years.112 
It is thus an idiosyncratic condition. On a clinical basis, the 
diagnosis is settled when four features of the syndrome are 
fulfilled: change of mental status, rigidity, hyperpyrexia, 
vegetative dysregulation of the autonomic nervous system 
(including blood pressure fluctuations). When any two of 
these above-mentioned features appear, diagnosis should 
be suspected within the setting of psychotropic drug therapy 
(when treating psychosis) or dopamine withdrawal (in cases 
of Parkinsonism). Withdrawal of therapy with intrathecal 
baclofen has, also in several cases, been associated with an 
NMS-like syndrome.113 The difference here is that increased 
muscular tone is of a rebound spastic-type rather than being 
a rigid one, otherwise the spectrum of symptoms appears 
quite identical to those of NMS. Clinicians have to take into 
consideration that the importance of differential diagnosis, 
including meningitis, encephalitis, septic shock (systemic 
infections), heat stroke, and other iatrogenic dysautono-
mias. Concerning the results from laboratory investiga-
tions, these should assist in ruling out the possibility of the 
above-mentioned tentative diagnoses, especially the elevated 
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observation in NMS although it is not a pathognomonic 
finding in the syndrome. The approach to a case of NMS, 
and its general management, should be based on a hierarchy 
of the severity of clinical features and thus enable the correct 
diagnosis to be made.44,71
Taken together, when there is any possible sugges-
tion of NMS, the administration of psychotropics should 
be stopped, and the patient should be admitted for close 
observation to evaluate the clinical signs and to perform the 
relevant laboratory investigations. This should be done in 
an ICU, especially for patients who have significant hyper-
pyrexia and rigidity. This is because these individuals need 
aggressive supportive care (see above). One should evaluate 
biological treatment with dantrolene, bromocriptine, and/or 
amantadine in patients who have significantly elevated CK 
values or hyperpyrexia on the first presentation, and in those 
who are irresponsive to withdrawal of a psychotropic drug 
(or the offending drug) within the first 48 hours of admission. 
Patients who do not respond to medical therapy during the 
first 7 days, especially those with persistent catatonia after 
the resolution of other symptoms, lethal catatonia should 
be regarded as an alternative diagnosis or as a concomitant 
sequel, then ECT should be seriously considered.114 Should 
the patient need antipsychotic therapy after NMS has sub-
sided, risk of the syndrome will still be there although it may 
be minimized if the following guidelines are followed:
1. Therapy should be postponed for at least 14 days or more, 
until all the residual symptoms have subsided (especially 
those of EPS).
2. An agent of lower potency should be chosen where the 
possibility of NMS relapse is minimal (or less likely).
3. The initial start dose should be the lowest possible (ie, 
lowest recommended), where the clinician can increase 
the dose gradually by titration in order to establish the 
lowest possible therapeutic level that clinically controls 
psychosis.
In cases where lithium is needed as an adjuvant medica-
tion, in addition to an antipsychotic agent (ie, when such a 
combination is indicated clinically), then the clinician should 
find another combination as an alternative treatment in order 
to avoid the use of lithium. This is simply because lithium, 
even as monotherapy, can potentially result in a relapse.115 
The patient has to be advised to drink sufficient amounts of 
liquids (water and alcohol-free beverages) to keep the body 
hydrated, to control body temperature, and to ensure proper 
kidney function. Environmental therapy has a very important 
role here, since patients should be under observation with 
respect to their fluid intake even when the patient is on an 
atypical antipsychotic therapy regime.23 Overhydration (water 
intoxication) has also been blamed for causing NMS,116 so 
a balanced water intake is a pivotal factor for both optimal 
metabolism and the pharmacology of the antipsychotic 
agent(s) the patient is using, and to maintain normal renal 
function. The patients themselves should be orientated and 
alerted about the early symptoms of possible relapse, and 
they should be called in to a psychiatric outpatient institution 
for a periodic checkup and clinical observation. As pointed 
out here, and also stated elsewhere, the real pathophysiology 
of psychosis is unknown and the dopamine hypothesis of 
psychosis alone can neither explain the biochemical basis 
of psychosis nor the pathophysiology of NMS. Indeed the 
psychotropic agents currently in use are not optimal for 
treatment of psychosis, simply because they are not selective 
enough in their actions. They can thus induce a huge number 
of known and unknown idiosyncratic devastating side effects, 
including the syndrome currently being discussed, namely 
NMS.117 The fight against psychosis with the design of better 
agents that possess more selective actions, such as mono-
therapy, will almost certainly continue for decades. Time and 
economic resources will be needed in addition to ambitious 
and devoted scientists to achieve this important goal. This 
will require that the scientists (biochemists, pharmaceutical 
chemists, and psychopharmacologists) will need to chan-
nel resources in the direction toward the area of psychosis, 
a currently unexplained and poorly investigated medical 
issue. Another aspect is, can we explain the pathophysiology 
of psychosis dependent only on the basis of receptor and 
ligand (neurotransmitter) interaction alone and treatment 
based on the receptor–drug theory of pharmacology? 
Furthermore, what about the intercalation mechanism of 
psychotropics into the membranal phospholipids of neurons 
and myocytes118 and the biomembranes of internal cellular 
organelles of these excitable cells, such as endoplasmic 
reticulum that releases intracellular calcium? The majority 
of agents that can initiate the onset of NMS, listed in Table 1 
have amphiphilic chemical structures,119,120 that is, they have 
lipophilic and hydrophilic moieties (Figure 1). This property 
makes these agents intercalate in-between the lipid tails of 
biomembrane phospholipids. This may plausibly explain why 
none of the psychotropics currently in use are selective for 
dopamine subtype D
2
 receptors (the proposed receptors for 
psychotropic drugs). We consider them as being nonselec-
tive because these agents often produce a spectrum of side 
effects that cannot be explained by solely being dependent 
on the receptor–drug theory. Indeed, most scientific research 






































































Powered by TCPDF (www.tcpdf.org)
                               1 / 1





Figure 1 Chemical structures of dopamine and some of the agents referred to in this work.
biomembrane integrity related to sound and normal neuronal 
function. The question that imposes itself in this context is 
the following: is there any significance, or therapeutic, or 
biological advantage for the use of micronutrients such as 
antioxidants, for example, selenium-containing compounds, 
the water soluble vitamins (C and B), the fat soluble vitamins 
(E and A), and the polyunsaturated fatty acids as adjuvants 
to psychotropics in order to minimize the possible occur-
rence of side effects including NMS? New psychotropics 
will have to be more selective and thus more potent against 
the proposed receptors that they are designed for. Evidence 
exists that some of the neuroleptics currently in use can 
release free radicals and these can precipitate NMS.121,122 
It would thus be logical to consider treating the syndrome 
with antioxidants, at least as adjuvant remedies.123 One inter-
esting issue concerning valproate is that it can precipitate 
NMS,124 but can also be used in treatment of this syndrome.125 
This illustrates the fact that we still know very little about 
the pathophysiology of this morbidity, and the exact cause 
of NMS is still unknown. More research must be done in 
order to elucidate these issues. It is highly likely that once 
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we will plausibly be able to answer the following question: 
how do psychotropics exert their pharmacologic function at 
the cellular (neuronal) level? Indeed these two issues (NMS 
and pharmacologic actions of antipsychotics) are two sides 
of the same coin, and each may aid in explaining the other. 
Currently available theories (or hypotheses) have limita-
tions in being able to explain all clinical manifestations of 
this syndrome and other complications that are precipitated, 
especially by antipsychotics in general.
One of the issues causing a great dilemma in NMS is the 
hyperpyrexia, where there is no convincing explanation for 
its pathophysiology. Animal model studies have shown that 
orexin-A (an excitatory neuropeptide) can cause thermogen-
esis in a manner unrelated to muscle activity. This action 
is controlled centrally via the sympathetic nervous system. 
This neuropeptide and its other isoforms are involved in 
controlling body temperature in a complex reaction with the 
dopaminergic pathways of the brain.126 In one experiment, 
an orexin-1 receptor antagonist (SB-334867) increased the 
number of naturally active dopamine neurons A9 and A10 
while the number was decreased by the action of acutely 
administered haloperidol or olanzapine. The same antagonist 
spontaneously decreased the number of active dopamine 
cells A9 and A10, that is, it caused the reverse. This animal 
model experiment indicates that the orexin-1 receptor plays 
a role in the effects of psychotropics on dopamine pathways, 
and probably the clinical effects of these agents (therapeutic 
and side effects).127 In another animal experiment, it was also 
demonstrated that the administration of quetiapine delays 
the sympathetic firing rate (muscle and colonic temperature 
and heart rate) caused by orexin-A injected into the lateral 
cerebral ventricle.128 In a similar experiment, this time with 
olanzapine, it was observed that this antipsychotic blocks the 
sympathetic firing rate, thus affecting muscular and colonic 
temperatures, and also heart rate.129 These experiments might 
give a clue regarding how certain psychotropics exert their 
pharmacologic effects, these could be therapeutic and/or 
undesired effects.
A final issue of importance that requires mention is the 
animal model of this syndrome, developed by methods 
of bioassay. This, however, does not correspond to the 
human variant of this syndrome,71,130 and is thus of no 
practical use.
Finally, it is crucial to gain an understanding of the 
pathophysiology of psychiatric diseases at the biomolecular 
level in neurons in order to be in a position to design more 
selective agents. These should be potent as well as being 
devoid of grave side effects, such as the induction of NMS.
Conclusion
As the majority of NMS cases have been attributed to the use 
of antipsychotic agents, especially first-generation (conven-
tional or typical) drugs, one should be careful when prescrib-
ing such agents to psychotic patients. The current trend in 
many psychiatric centers of the developed world is the use of 
second-generation (atypical) agents. NMS, however, has not 
been totally abolished.131 In other words, the syndrome can 
still be encountered even with the availability of the second-
generation of newly designed agents,132 although the clinical 
picture might be milder than what is encountered in NMS 
with typical antipsychotics.10,11 Amisulpride, a relatively 
newly designed atypical antipsychotic, has also been shown 
to be associated with the occurrence of NMS.133 This has to 
be attributed to the fact that we do not know the nature of 
the exact biological changes that occur in the neurons of 
psychotic patients. Once we have understood this dilemma, 
we can then prepare better agents with least possible side 
effects. It is also necessary to mention here that the use of 
drugs other than antipsychotic agents can lead to NMS, 
for example, drugs such as metoclopramide (antiemetic), 
amoxapine (tetracyclic antidepressant), and lithium (mood 
stabilizer) have been recognized as being perpetrators of 
NMS.134 In other words, it is not only antipsychotics alone 
that should be blamed for being behind the occurrence of 
this syndrome. A retrospective survey on patients in a study 
showed that citalopram (an SSRI antidepressant) can trig-
ger acute dystonia which could be the prodromal stage of 
NMS.135 The same thing is also true for metoclopramide 
(Table 1), and as stated before, this indeed makes the predic-
tion of NMS almost impossible. It is likely that the number of 
agents that can precipitate NMS will most probably increase 
year by year. Because there is no pathognomonic laboratory 
test to pinpoint the diagnosis of this idiosyncratic syndrome, 
careful periodic clinical observation of psychotic patients 
is warranted, especially those who have recently started 
taking antipsychotics (particularly those being treated with 
oily depot injections of long-acting potent first-generation 
drugs in outpatient clinics of psychiatric centers). This 
action may help the early diagnosis of NMS and thus ensure 
an early start of treatment intervention with the hope of 
minimum negative consequences. It is clear that the major-
ity of drugs that are associated with the induction of NMS 
are either antipsychotics or antidepressants. These groups 
of drugs are cornerstones as biological treatment tools in 
contemporary clinical psychiatry. It is evident that these 
drugs have no selective actions when prescribed as mono-
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a fact that increases the spectrum of anticipated side effects, 
including NMS.136,137
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The authors report no conflicts of interest in this work.
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